IP Library Granted Patent US 12,233,205
Granted Patent B2
US 12,233,205 · App. 17/341,994 · Granted Feb 25, 2025

Thermal modulation of an inhalable medicament

Inventor: Noah Mark Minskoff (Palo Alto, CA)
Assignee: Michael Edward Breede
A61M15/0036A61M11/02A61M11/041A61M15/009A61M39/00A61M2039/0036A61M2205/123
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,205
App. No.
17/341,994
Granted
Feb 25, 2025
Kind
B2
Abstract

A thermally modulating inhalable medicament delivery device may deliver an inhalable medicament as an aerosol, vapor, or partial aerosol and partial vapor mixture to a subject. The inhalable medicament may be delivered to a targeted location in an airway of the subject. Various other devices, systems, and methods for delivering an inhalable medicament to a subject are also disclosed.

Claims (41)

1. A tamper-resistant cartridge for an inhalable medicament delivery device, comprising:

a medicament;

a penetrable seal that enables the inhalable medicament delivery device to controllably release the medicament from the tamper-resistant cartridge;

a neutralizing agent that, upon contacting the medicament, renders the medicament inaccessible or functionally neutralized; and

an encapsulation creating a barrier between the neutralizing agent and the medicament, the encapsulation, when penetrated during efforts to remove the medicament from the tamper-resistant cartridge without the inhalable medicament delivery device, releases the neutralizing agent into contact with the medicament.

2. The tamper-resistant cartridge of claim 1 , wherein the encapsulation ruptures when the medicament is accessed in a manner corresponding to activation of a reservoir tap of the inhalable medicament delivery device.

3. The tamper-resistant cartridge of claim 1 , wherein the neutralizing agent, when in contact with the medicament, reacts with the medicament to render the medicament inaccessible or functionally neutralized.

4. The tamper-resistant cartridge of claim 1 , wherein the neutralizing agent comprises an absorbent material.

5. The tamper-resistant cartridge of claim 4 , wherein the absorbent material comprises charcoal.

6. The tamper-resistant cartridge of claim 1 , further comprising: a porous reservoir material carrying the medicament.

7. The tamper-resistant cartridge of claim 1 , wherein the encapsulation and the penetrable seal collectively surround an entirety of the medicament.

8. The tamper-resistant cartridge of claim 1 , wherein the encapsulation comprises a medicament bladder that, along with an interior surface of the penetrable seal, defines a reservoir for the medicament and separating the medicament from the neutralizing agent.

9. The tamper-resistant cartridge of claim 8 , further comprising:

a neutralizing bladder surrounding the medicament bladder and the neutralizing agent and holding the neutralizing agent against an outside of the medicament bladder.

10. A tamper-resistant cartridge for an inhalable medicament delivery device, comprising:

a medicament;

a penetrable seal that enables the inhalable medicament delivery device to controllably release the medicament from the tamper-resistant cartridge;

a neutralizing agent that, upon contacting the medicament, renders the medicament inaccessible or functionally neutralized; and

a barrier between the neutralizing agent and the medicament, the barrier, when penetrated during efforts to remove the medicament from the tamper-resistant cartridge without activation of a reservoir tap of the inhalable medicament delivery device, releases the neutralizing agent into contact with the medicament.

11. The tamper-resistant cartridge of claim 10 , wherein the barrier and the penetrable seal collectively surround an entirety of the medicament.

12. The tamper-resistant cartridge of claim 10 , wherein the neutralizing agent comprises an absorbent material.

13. The tamper-resistant cartridge of claim 10 , further comprising:

a pressure plate that moves within the tamper-resistant cartridge to controllably force the medicament from the tamper-resistant cartridge.

14. The tamper-resistant cartridge of claim 13 , wherein a position of the pressure plate within the tamper-resistant cartridge is indicative of a volume of the medicament and/or a number of doses of the medicament remaining within the tamper-resistant cartridge.

15. The tamper-resistant cartridge of claim 13 , wherein movement of the pressure plate that does not correspond to an intentional activation of the inhalable medicament delivery device renders the tamper-resistant cartridge and the inhalable medicament delivery device inactive.

16. The tamper-resistant cartridge of claim 10 , wherein the neutralizing agent, when in contact with the medicament, reacts with the medicament to render the medicament inaccessible or functionally neutralized.

17. The tamper-resistant cartridge of claim 10 , wherein the neutralizing agent comprises an absorbent material.

18. A tamper-resistant inhalable medicament delivery system, comprising:

a cartridge containing a medicament and including:

a penetrable seal that provides selective access to the medicament; and

a pressure plate that forces the medicament from the cartridge, through the penetrable seal; and

an inhalable medicament delivery device including:

a reservoir tap that cooperates with the penetrable seal to selectively access the medicament; and

electronics that determine a position of the pressure plate within the cartridge and deactivate the cartridge and/or the inhalable medicament delivery device when the position of the pressure plate does not correspond to an intentional activation of the cartridge.

19. The tamper-resistant inhalable medicament delivery system of claim 18 , wherein the electronics of the inhalable medicament delivery device deactivate the cartridge and/or the inhalable medicament delivery device when the position of the pressure plate is indicative of tampering with, damage to, or malfunctioning of the cartridge.

20. The tamper-resistant inhalable medicament delivery system of claim 18 , wherein the electronics of the inhalable medicament delivery device, based on movement and/or a position of the pressure plate of the cartridge, determine at least one of:

a volume of the medicament delivered by the cartridge;

a number of doses of the medicament delivered by the cartridge;

a volume of each dose of the medicament delivered by the cartridge;

a volume of the medicament remaining in the cartridge; and

a number of doses of the medicament remaining in the cartridge.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2021
From: BANKRUPTCY ESTATE OF INNOVOSCIENCES LLC
To: BREEDE, MICHAEL EDWARD
Reel/Frame 057451/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2021
From: MINSKOFF, NOAH MARK
To: INNOVOSCIENCES LLC
Reel/Frame 057471/0243 →
Continuity (8)
Division 16990930 · Aug 11, 2020
Continuation 16424459 · May 28, 2019
Continuation In Part 14835595 · Aug 25, 2015
Provisional Application 62061956 · Oct 9, 2014
Provisional Application 62061669 · Oct 8, 2014
Provisional Application 62042224 · Aug 26, 2014
Provisional Application 62187289 · Jul 1, 2015
Related Publication 20210299368A1 · Sep 30, 2021
References Cited (73)
US 3761285A · Nagasawa et al. · 1973 [cited by applicant]
US 5060671A · Counts et al. · 1991 [cited by applicant]
US 5388594A · Counts et al. · 1995 [cited by applicant]
US 5662271A · Weston et al. · 1997 [cited by applicant]
US 5666977A · Higgins et al. · 1997 [cited by applicant]
US 5957124A · Lloyd et al. · 1999 [cited by applicant]
US 6054082A · Heide et al. · 2000 [cited by applicant]
US 6086582A · Altman et al. · 2000 [cited by applicant]
US 6250508B1 · Geser et al. · 2001 [cited by applicant]
US 6595209B1 · Rose et al. · 2003 [cited by applicant]
US 6948496B2 · Eason et al. · 2005 [cited by applicant]
US 7021559B2 · Fraser-Easton · 2006 [cited by applicant]
US 7186958B1 · Nelson · 2007 [cited by applicant]
US 7458373B2 · Nichols · 2008 [cited by examiner]
US 7722838B2 · Hyacinthe · 2010 [cited by examiner]
US 8210166B2 · Denton et al. · 2012 [cited by applicant]
US 8434477B2 · De Vos · 2013 [cited by applicant]
US 8490795B2 · Ziemba · 2013 [cited by examiner]
US 8523843B2 · Kavanagh et al. · 2013 [cited by applicant]
US 8584673B2 · Thoemmes et al. · 2013 [cited by applicant]
US 8758323B2 · Michaud et al. · 2014 [cited by applicant]
US 9061879B2 · Patthey · 2015 [cited by examiner]
US 9364841B2 · Dunne et al. · 2016 [cited by applicant]
US 9489491B2 · Chrusciel · 2016 [cited by examiner]
US 10300228B2 · Minskoff · 2019 [cited by applicant]
US 10737042B2 · Minskoff · 2020 [cited by applicant]
US 11052202B2 · Parry-Billings · 2021 [cited by examiner]
US 20030230303A1 · Nichols et al. · 2003 [cited by applicant]
US 20040118396A1 · Hughes et al. · 2004 [cited by applicant]
US 20040163645A1 · Connelly et al. · 2004 [cited by applicant]
US 20070151560A1 · Price et al. · 2007 [cited by applicant]
US 20070221216A1 · Ganem et al. · 2007 [cited by applicant]
US 20070250007A1 · Shekalim · 2007 [cited by applicant]
US 20080135047A1 · Johnson et al. · 2008 [cited by applicant]
US 20090223994A1 · Getz · 2009 [cited by examiner]
US 20090240196A1 · Truax · 2009 [cited by applicant]
US 20100043792A1 · Takei · 2010 [cited by applicant]
US 20100059049A1 · Genosar · 2010 [cited by applicant]
US 20100108062A1 · Ganem et al. · 2010 [cited by applicant]
US 20110094523A1 · Thorens et al. · 2011 [cited by applicant]
US 20110168175A1 · Dunne et al. · 2011 [cited by applicant]
US 20110290243A1 · Bach et al. · 2011 [cited by applicant]
US 20120103326A1 · Karle et al. · 2012 [cited by applicant]
US 20120132204A1 · Lucking et al. · 2012 [cited by applicant]
US 20130239964A1 · Young et al. · 2013 [cited by applicant]
US 20130317477A1 · Edwards et al. · 2013 [cited by applicant]
US 20140118396A1 · Sugita et al. · 2014 [cited by applicant]
US 20150320936A1 · Dunne · 2015 [cited by applicant]
US 20160030181A1 · Forsell · 2016 [cited by applicant]
US 20170007775A1 · Bengtsson et al. · 2017 [cited by applicant]
EP 1867357A1 · 2007 [cited by applicant]
JP 2001509761A · 2001 [cited by applicant]
JP 2009034576A · 2009 [cited by applicant]
JP 2012122671A · 2012 [cited by applicant]
WO 1996028205A1 · 1996 [cited by applicant]
WO 2008040841A1 · 2008 [cited by applicant]
Japan Patent Office, “Office Action,” Japanese Application No. 2022-002443, Nov. 28, 2022. [cited by applicant]
Canadian Intellectual Property Office, “Examiner's Requisition,” Canadian Application No. 2996047, Feb. 8, 2023. [cited by applicant]
Japan Patent Office, “Second Office Action,” Japanese Application No. 2020-178989, Jan. 24, 2022. [cited by applicant]
Japan Patent Office, “Office Action,” Japanese Application No. 2022-002443, Jun. 22, 2023. [cited by applicant]
Canadian Intellectual Property Office, “Examiner's Requisition,” Canadian Application No. 2996047, Mar. 20, 2024. [cited by applicant]
Japan Patent Office, “Decision of Rejection,” Japanese Application No. 2022-002443, Mar. 27, 2024. [cited by applicant]
Japan Patent Office, “Notice of Allowance,” Japanese Application No. 2020-178989, Jun. 1, 2022. [cited by applicant]
Canadian Intellectual Property Office, “Examiner Requisition,” Canadian Application No. 2996047, Jun. 3, 2022. [cited by applicant]
European Patent Office, “Extended European Search Report,” European Application No. 15835153.6, Mar. 26, 2018. [cited by applicant]
USPTO as International Searching Authority, “International Search Report and Written Opinion,” International Application No. PCT/US2015/047037, Feb. 1, 2016. [cited by applicant]
Japan Patent Office, “Office Action,” Japanese Application No. 2017-530964, May 22, 2019. [cited by applicant]
Fernandez Tena, A., et al., “Deposition of Inhaled Particles in the Lungs,” Arch Bronconeumol. 48(7):240-246 (2012). [cited by applicant]
Zarogouldis, P., et al., “Vectors for Inhaled Gene Therapy in Lung Cancer Application for Nano Oncology and Safety of Bio Nanotechnology,” Int. J. Mol. Sci. 13:10828-10862 (2012). [cited by applicant]
China National Intellectual Property Administration, “First Office Action,” Chinese Application No. 201580057946.4, Aug. 1, 2019. [cited by applicant]
Japan Patent Office, “Second Office Action,” Japanese Application No. 2017-530964, Mar. 3, 2020. [cited by applicant]
Japan Patent Office, “First Office Action,” Japanese Application No. 2020-178989, mailed Jul. 14, 2021. [cited by applicant]
Canadian Intellectual Property Office, “Examiner's Report,” Canadian Application No. 2996047, Oct. 14, 2021. [cited by applicant]